Shikari® (S-ATP) Anti-Pembrolizumab ELISA w/confirmation
PEM-QNS-KEY
Enzyme immunoassay for the quantitative determination (screening) of antibodies to Pembrolizumab (Keytruda®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative determination of antibodies to pembrolizumab in serum and plasma samples.
Pembrolizumab (Keytruda®) was associated to the development of anti-Pembrolizumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Keytruda®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Pembrolizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Pembrolizumab antibodies.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 7,5 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Martinez, C., et al. "374P: Prognostic relevance of post-cycle 1 pembrolizumab levels in real-world NSCLC patients receiving first line IO or ChIO." Journal of Thoracic Oncology 20.3 (2025): S220-S221. | Visit Link | |
| Martínez-Toledo, Cristina, et al. "Early Pembrolizumab Plasma Levels as a Prognostic Biomarker in Real-World NSCLC Patients." Pharmacological Research (2026): 108232. | Download | |
| Vázquez-Quiroga, Sara, et al. "Evaluation of the exposure-response relationship of pembrolizumab in non-small cell lung cancer: observational study protocol in real-world clinical practice." BMC Cancer 26.1 (2026): 630. | Visit Link |
